Skip to main content
Haisco Pharmaceutical Group Co.,Ltd logo

Haisco Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 002653 ISIN · CNE100001BC7 LEI · 300300GRLH34A8GPJ639 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,439 across all filing types
Latest filing 2024-01-17 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002653

About Haisco Pharmaceutical Group Co.,Ltd

https://www.haisco.com

Haisco Pharmaceutical Group Co.,Ltd. focuses on the research, development, production, and commercialization of innovative drugs and high-end generic pharmaceuticals. The company maintains a specialized portfolio across therapeutic areas including anesthesia, parenteral nutrition, anti-infection, cardiovascular health, and endocrine disorders. Key products include advanced anesthetic agents and specialized nutritional injections designed for clinical use. Haisco prioritizes technological innovation through a dedicated R&D infrastructure, targeting the development of small molecule chemical drugs and complex delivery systems. Its operations emphasize high-standard manufacturing processes and the integration of clinical research to address complex medical requirements. The company aims to provide therapeutic solutions that enhance patient care through a commitment to scientific excellence and product quality.

Recent filings

Filing Released Lang Actions
关于为子公司借款提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement by the company Hai Si Ke Pharmaceutical Group Co., Ltd. regarding the provision of a guarantee for a loan taken by its subsidiary. It details the board meeting approval, the subsidiary's financial status, the guarantee terms, and cumulative guarantees. The document is an announcement about a financing-related event (loan guarantee) rather than a financial report or earnings release. It does not contain comprehensive financial statements or quarterly results, nor is it a regulatory certification or voting result. The content fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities and guarantees provided for loans.
2024-01-17 Chinese
关于获得创新药HSK39297片新适应症IND申请《受理通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acceptance of an IND (Investigational New Drug) application for a new indication of an innovative drug by the National Medical Products Administration (国家药品监督管理局). It includes details about the drug, its clinical trial status, and a risk warning to investors. The document is short (972 characters) and is an official announcement of regulatory acceptance rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or detailed report data. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2024-01-11 Chinese
关于获得创新药HSK16149胶囊新适应症IND申请《受理通知书》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a pharmaceutical company about receiving an acceptance notice from the National Medical Products Administration for a new drug indication clinical trial application. It details the drug, its intended use, regulatory acceptance, and risk warnings. The document is short (1469 characters) and does not contain financial data, earnings, or detailed report content. It is an official announcement of a regulatory acceptance related to drug development, not a financial report or management information. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-01-10 Chinese
华泰联合证券有限责任公司关于海思科医药集团股份有限公司2023年度持续督导工作现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "现场检查报告" (On-site Inspection Report) conducted by 华泰联合证券有限责任公司 (Huatai United Securities Co., Ltd.) regarding 海思科医药集团股份有限公司 (Haisco Pharmaceutical Group Co., Ltd.) for the year 2023. It references regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange guidelines related to sponsorship and supervision of the company. The report covers detailed findings on corporate governance, internal controls, information disclosure, use of raised funds, and performance, including specific compliance checks and audit-like procedures. It is a standalone audit or inspection report rather than a full annual or interim financial report. The document length is 4368 characters, which is relatively short but contains substantive content rather than just an announcement or certification. It is not a simple announcement of a report publication, nor a certification letter. Therefore, it fits best under the category of Audit Report / Information (AR). FY 2023
2024-01-08 Chinese
华泰联合证券有限责任公司关于海思科医药集团股份有限公司2023年度持续督导培训情况报告
Regulatory Filings Classification · 95% confidence The document is titled as a "持续督导培训情况报告" which translates to "Continuous Supervision Training Report" for the year 2023. It is issued by Huatai United Securities Co., Ltd. as the sponsor institution for Hisun Pharmaceutical Group Co., Ltd. The content describes a training session conducted for the company's directors, supervisors, senior management, controlling shareholders, and board office staff, focusing on regulatory compliance and governance. The document is a report on the training activities and their effectiveness, not a financial report, earnings release, or regulatory filing. It is also not an announcement of voting results, capital changes, or management changes. The document is relatively short (1257 characters) and is a formal report on a specific training event related to regulatory supervision. This fits best under Regulatory Filings (RNS) as it is a compliance-related report that does not fit other specific categories.
2024-01-08 Chinese
关于控股股东部分股份解除质押的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding the release of pledged shares by a controlling shareholder of the company. It details the number of shares released from pledge, the shareholder's name, and related shareholding percentages. There is no financial data, no mention of financial results, no management discussion, no legal proceedings, or other report types. The document is a notification about changes in share pledges by a major shareholder, which fits the category of Major Shareholding Notification (MRQ). The document length is short and focused solely on shareholding changes, not a full report or announcement of a report publication.
2024-01-08 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.